SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-001482
Filing Date
2024-01-03
Accepted
2024-01-03 16:02:09
Documents
13
Period of Report
2023-12-29
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d641060d8k.htm   iXBRL 8-K 25704
  Complete submission text file 0001193125-24-001482.txt   182645

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20231229.xsd EX-101.SCH 3882
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE qncx-20231229_def.xml EX-101.DEF 13697
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20231229_lab.xml EX-101.LAB 22681
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20231229_pre.xml EX-101.PRE 14665
7 EXTRACTED XBRL INSTANCE DOCUMENT d641060d8k_htm.xml XML 5179
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 24506199
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)